BioPharm International
October 02, 2008
Articles
2008 Supplement
6
NeisVac-C is a polysaccharide-protein conjugate vaccine for use against Neisseria meningitidis serogroup C infection. The Phase 1 clinical formulation consisted of physiological saline, thimerosal, and aluminum hydroxide. The long-term stability data for both the PBS and saline formulations are presented in this article.
October 02, 2008
Articles
2008 Supplement
6
Interview with Roger Lias, president and group commercial director at Eden Biodesign, Inc.
October 02, 2008
Articles
2008 Supplement
6
This article discusses the production process of the major influenza antigen, hemagglutinin (HA), by rDNA methods in E. coli.
October 02, 2008
Articles
2008 Supplement
6
Interview with Magda Marquet, co-CEO and co-president of Althea Technologies
October 02, 2008
Articles
2008 Supplement
6
There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
October 02, 2008
Articles
2008 Supplement
6
The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
October 02, 2008
Articles
2008 Supplement
6
To succeed in a pandemic, the industry must forge a preparedness plan to ensure adequate vaccines.